This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n7https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n15http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
freebasehttp://rdf.freebase.com/ns/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Prostvac
rdf:type
wikidata:Q8386 dbo:Drug n15:ChemicalObject dbo:ChemicalSubstance owl:Thing dbo:Vaccine dbo:Person
rdfs:label
Prostvac
rdfs:comment
PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA).
dct:subject
dbc:Prostate_cancer dbc:Cancer_vaccines
dbo:wikiPageID
44285932
dbo:wikiPageRevisionID
1099695334
dbo:wikiPageWikiLink
dbr:National_Cancer_Institute dbr:Poxviridae dbr:Gene_cassette dbr:Immune_response dbr:LFA-3 dbr:B7.1 dbr:Vaccine dbr:Prostate-specific_antigen dbr:Immune_checkpoint dbr:Prostate_cancer dbr:Subcutaneous_injection dbr:Bavarian_Nordic dbr:Fowlpox dbr:Cancer_immunotherapy dbc:Prostate_cancer dbc:Cancer_vaccines dbr:ICAM-1 dbr:Vaccinia dbr:Bristol-Myers_Squibb dbr:Cooperative_research_and_development_agreement
owl:sameAs
n7:2Mtsi yago-res:Prostvac wikidata:Q25091283 freebase:m.0127xx16
dbp:wikiPageUsesTemplate
dbt:Vaccines dbt:Cn dbt:Vaccine-stub dbt:Drugbox
dbp:casNumber
947602
dbp:chemspiderid
none
dbp:routesOfAdministration
dbr:Subcutaneous_injection
dbp:target
dbr:Prostate_cancer
dbp:type
vaccine
dbo:abstract
PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) is a cancer immunotherapy candidate in clinical development by Bavarian Nordic for the treatment of all prostate cancer although clinical trials are focusing on more advanced cases of metastatic castration-resistant prostate cancer (mCRPC). PROSTVAC is a vaccine designed to enable the immune system to recognize and attack prostate cancer cells by triggering a specific and targeted T cell immune response to cancer cells that express the tumor-associated antigen prostate-specific antigen (PSA). PROSTVAC utilizes recombinant poxviruses that express PSA, along with 3 immune-enhancing costimulatory molecules collectively designated as TRICOM (LFA-3, ICAM-1, and B7.1) to stimulate an immune response. Treatment is initiated by subcutaneous administration of a priming dose of vaccinia encoding PSA-TRICOM, followed by 6 subsequent boosting doses of fowlpox encoding the same PSA-TRICOM cassette. Using this heterologous prime-boost dosing regimen, the immune system becomes focused on inducing PSA-specific T cell responses, designed to kill tumor cells expressing PSA.
dbp:pubchemsubstance
534055
gold:hypernym
dbr:Candidate
prov:wasDerivedFrom
wikipedia-en:Prostvac?oldid=1099695334&ns=0
dbo:wikiPageLength
5980
dbo:casNumber
947602-09-7
foaf:isPrimaryTopicOf
wikipedia-en:Prostvac